Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease-Reference-Cited by-同舟云学术

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Published:2021-07 Issue: Volume:114 Page:103641
ISSN:1044-7431
Container-title:Molecular and Cellular Neuroscience
language:en
Short-container-title:Molecular and Cellular Neuroscience

Author:

Johannesson Malin,Sahlin Charlotte,Söderberg Linda,Basun Hans,Fälting Johanna,Möller Christer,Zachrisson Olof,Sunnemark Dan,Svensson Anne,Odergren Tomas,Lannfelt Lars

Publisher

Elsevier BV

Subject

Cell Biology,Cellular and Molecular Neuroscience,Molecular Biology

Reference40 articles.

1. Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain;Alic;Mol. Psychiatry,2020

2. The pattern of amyloid accumulation in the brains of adults with Down syndrome;Annus;Alzheimers Dement.,2016

3. Elucidating Pathogenic Mechanisms of Early-onset Alzheimer’s Disease in Down Syndrome Patients;Asai;Yakugaku Zasshi,2017

4. Methodological variables in the assessment of beta amyloid neurotoxicity;Busciglio;Neurobiol. Aging,1992

5. Correlations of synaptic and pathological markers with cognition of the elderly;Dickson;Neurobiol. Aging,1995

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LPS priming before plaque deposition impedes microglial activation and restrains Aβ pathology in the 5xFAD mouse model of Alzheimer’s disease;Brain, Behavior, and Immunity;2023-10

2. A Comprehensive Review of Essential Oils and Their Pharmacological Activities in Neurological Disorders: Exploring Neuroprotective Potential;Neurochemical Research;2023-09-28

3. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer’s disease treatment;Inflammation Research;2023-09

4. Abundant Aβ fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer’s disease brains;Neuron;2023-07

5. Food and Drug Administration Accelerated Approval of Lecanemab for Early Alzheimer's Disease—Hope, Reality, and the Unknown Going Forward;Clinical Nurse Specialist;2023-05